

AMENDMENTS TO THE SPECIFICATION

Page 1, after the title insert the following:

This application is the US national phase of international application **PCT/CH2004/000363** filed **16 June 2004** which designated the U.S. and claims benefit of **PCT/CH2003/00398**, dated **19 June 2003**, the entire content of which is hereby incorporated by reference.

Please amend the paragraph beginning at page 5, line 6, as follows:

Primary hepatocytes do not proliferate, thus production of proteins from this type of cells requires a steady supply of new cellular preparations from human liver biopsies. This would represent a clumsy and expensive approach with many associated problems (QA, batch-to-batch variability, almost no standardization, regulatory hassle). This issue has been solved through ~~TGE-Corp's in-licensing strategy~~ (Multicell Technologies' unique immortalized and standardized fully competent human hepatocytes).

Please amend the paragraph beginning at page 5, line 16, as follows:

Any other therapeutic protein candidate will have to be produced using genetic engineering strategies. However, even in this case, the human nature/origin of these cellular substrates (~~MCT's hepatic cell lines~~) should guarantee the best post-translational modification process currently available, thus leading to recombinant end-products with clear competitive advantages, including a favourable regulatory outlook.